Drugs / IONIS ANGPTL3-LRx
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02709850 | Nov 2015 → Apr 2017 | familial hypercholesterolemia, hypertriglyceridemia | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IONIS ANGPTL3-LRx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02709850 ↗ |
| Action | Inhibit | “After 6 weeks of treatment, persons in the multiple-dose groups had reductions in levels of ANGPTL3 protein” PMID 28538111 ↗ May 2017 |
| Modality | Antisense oligonucleotide | “Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.” PMID 28538111 ↗ May 2017 |
| Route | Subcutaneous | “subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA” PMID 28538111 ↗ May 2017 |
| Target | ANGPTL3 | “Use of the same strategy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans.” PMID 28538111 ↗ May 2017 |